Consensus molecular subtype 4 (CMS4)-targeted therapy in primary colon cancer: A proof-of-concept study.
Peters NA, Constantinides A, Ubink I, van Kuik J, Bloemendal HJ, van Dodewaard JM, Brink MA, Schwartz TP, Lolkema MPJK, Lacle MM, Moons LM, Geesing J, van Grevenstein WMU, Roodhart JML, Koopman M, Elias SG, Borel Rinkes IHM, Kranenburg O.
Peters NA, et al. Among authors: elias sg.
Front Oncol. 2022 Sep 6;12:969855. doi: 10.3389/fonc.2022.969855. eCollection 2022.
Front Oncol. 2022.
PMID: 36147916
Free PMC article.